Adc Therapeutics Sa Revenue Growth Rates (ADCT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Adc Therapeutics Sa  (NYSE: ADCT)
 

ADCT's Revenue Growth by Quarter and Year

Adc Therapeutics Sa's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ADCT/growth
https://api.csimarket.com/api/v1/companies/ADCT/fundamentals
https://api.csimarket.com/api/v1/companies/ADCT/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ADCT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 21.72
2nd Quarter June 19.25
1st Quarter March 20.85
FY 61.82

ADCTs Annual Revenue
Adc Therapeutics Sa's Revenue in the fiscal year 2025 $ 81.36 millions
Adc Therapeutics Sa's Revenue in the fiscal year 2024 $ 70.84 millions
Adc Therapeutics Sa's Revenue in the fiscal year 2023 $ 69.56 millions
Adc Therapeutics Sa's Revenue in the fiscal year 2022 $ 209.91 millions
Adc Therapeutics Sa's Revenue in the fiscal year 2021 $ 33.92 millions




ADCT Revenue third quarter 2026 Y/Y Growth Comment
Adc Therapeutics Sa reported Revenue improvement of 32.17% year on year in the third quarter 2026, to $ 21.72 millions, this is lower than Adc Therapeutics Sa's recent average Revenue improvement of 37.96%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 128 other companies have achieved higher Revenue growth. While Adc Therapeutics Sa' s Revenue rise of 32.17% ranks overall at the positon no. 2618 in the third quarter 2026.


ADCT Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 32.17 %
2nd Quarter June 2.18 %
1st Quarter March -9.47 %
FY   -

Financial Statements
Adc Therapeutics Sa's third quarter 2026 Revenue $ 21.72 millions ADCT's Income Statement
Adc Therapeutics Sa's third quarter 2025 Revenue $ 16.43 millions Quarterly ADCT's Income Statement


ADCT Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 12.81 %
2nd Quarter June -7.67 %
1st Quarter March -9.58 %
FY (Year on Year)   -


Back to ADCT Growth rate Comparisons >> Back to ADCT Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #129
Healthcare Sector #370
Overall #2618

Revenue Y/Y Growth Statistics
High Average Low
518.89 % 37.96 % -92 %
(Dec 31 2022)   (Dec 31 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #129
Healthcare Sector #370
Overall #2618
Revenue Y/Y Growth Statistics
High Average Low
518.89 % 37.96 % -92 %
(Dec 31 2022)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Adc Therapeutics Sa's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
341.39 % 19.9 % -90.95 %
0  


ADCT's III. Quarter Q/Q Revenue Comment
Adc Therapeutics Sa achieved in the III. Quarter 2026 below company average Revenue rise of 12.81% quarter on quarter, to $ 21.72 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -12.79% growth in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 116 other companies have achieved higher Revenue quarter on quarter growth. While Adc Therapeutics Sa's Revenue growth quarter on quarter, overall rank is 2711.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #117
Healthcare Sector #338
Overall #2711
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #117
Healthcare Sector #338
Overall #2711
Revenue Q/Q Growth Statistics
High Average Low
341.39 % 19.9 % -90.95 %
0  


ADCT's III. Quarter Q/Q Revenue Comment
Adc Therapeutics Sa achieved in the III. Quarter 2026 below company average Revenue rise of 12.81% quarter on quarter, to $ 21.72 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -12.79% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 116 other companies have achieved higher Revenue quarter on quarter growth. While Adc Therapeutics Sa's Revenue growth quarter on quarter, overall rank is 2711.


Adc Therapeutics Sa's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 84.87
Y / Y Revenue Growth (TTM) 12.85 %
Year on Year Revenue Growth Overall Ranking # 1052
Seqeuential Revenue Change (TTM) 6.65 %
Seq. Revenue Growth (TTM) Overall Ranking # 2390


Cumulative Revenue growth Comment
Although Adc Therapeutics Sa's Annual Revenue growth year on year were below company's average 37.81% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 12.85% year on year, from 3.03% in Jun 30 2026.

In the Healthcare sector 202 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1052, from total ranking in previous quarter at 2934.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 113
Healthcare Sector # 203
Overall # 1052

Revenue TTM Y/Y Growth Statistics
High Average Low
931.98 %
 37.81 %
-80.13 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 113
Sector # 348
S&P 500 # 2390
Cumulative Revenue growth Comment
Although Adc Therapeutics Sa's Annual Revenue growth year on year were below company's average 37.81% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 12.85% year on year, from 3.03% in Jun 30 2026.

In the Healthcare sector 202 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1052, from total ranking in previous quarter at 2934.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 113
Healthcare Sector # 203
Overall # 1052

Revenue TTM Y/Y Growth Statistics
High Average Low
931.98 %
37.81 %
-80.13 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 113
Sector # 348
S&P 500 # 2390




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ADCT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions
Travere Therapeutics Inc 36.22%$ 36.215 millions
Omada Health Inc 36.13%$ 36.133 millions
Guardant Health Inc 36.12%$ 36.116 millions


About Adc Therapeutics Sa Revenue Growth Rates (ADCT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Adc Therapeutics Sa (CIK 1771910).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-072178
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Adc Therapeutics Sa’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.